CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.

Eribulin, a non-taxane inhibitor of microtubule dynamics, is approved for the treatment of metastatic breast cancer patients after progression with anthracyclines and taxanes. Nevertheless, to our knowledge, information on its use in dialytic patients is not available to date. This report describes the case of a chemo-pretreated dialytic woman with lung, bone, and liver metastasis from breast cancer, who experienced stable disease with a response < 20% with eribulin in fifth line after 3 hormonal lines and 1 chemotherapy line. This case suggests the feasibility and good tolerability of eribulin in this peculiar setting.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app